Skip to content

Application of dexmedetomidine hydrochloride nasal spray in the treatment of insomnia

Application of dexmedetomidine hydrochloride nasal spray in the treatment of insomnia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120585
Enrollment
Unknown
Registered
2026-03-17
Start date
2026-03-20
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Disorders

Interventions

Group DEX:In addition to the treatment of insomnia using cognitive behavioral therapy combined with stellate ganglion block, dexmedetomidine nasal spray is administered: one spray per nostril 15 minut
Group NS:In addition to the treatment of insomnia using cognitive behavioral therapy combined with stellate ganglion block, use a saline nasal spray: apply one spray per nostril 15 minutes before bedt

Sponsors

Nanchang Hongdu Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for insomnia; 2. Be between the ages of 18 and 70 (inclusive); 3. Be aware of and understand the details of this study and sign the relevant informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with allergies to medications (such as dexmedetomidine hydrochloride nasal spray, local anesthetics, etc.); 2. Patients with cardiac conduction abnormalities or a recent history of myocardial infarction; 3. Patients with severe trauma or systemic diseases; 4. Patients with impaired consciousness, cognitive dysfunction, or acute or chronic pain; 5. Pregnant women (or those planning to become pregnant) and lactating women; 6. Patients with coagulation disorders or infection at the puncture site; 7. Patients with psychiatric disorders or poor compliance who cannot cooperate with treatment; 8. Patients deemed unsuitable for participation in this study by the investigator for other reasons.

Design outcomes

Primary

MeasureTime frame
Polysomnography (PSG) shows the proportion of N3 stage sleep;

Secondary

MeasureTime frame
Serum cortisol levels;Pittsburgh Sleep Quality Index;Insomnia Severity Index Scale;Hamilton Depression Scale;Hamilton Anxiety Scale;

Countries

China

Contacts

Public ContactLi Yafeng

Nanchang Hongdu Traditional Chinese Medicine Hospital

306293801@qq.com+86 137 6711 4105

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026